Third Harmonic Bio to Participate in Upcoming Investor Conferences in November

THRD 11.07.2024

Full Press ReleaseSEC FilingsOur THRD Tweets

About Gravity Analytica

Recent News

  • 12.04.2024 - Evercore HealthCONx Conference
  • 11.25.2024 - Third Harmonic Bio to Participate in the 7th Annual Evercore HealthCONx Conference
  • 11.19.2024 - Stifel 2024 Healthcare Conference

Recent Filings

  • 01.17.2025 - 4 Statement of changes in beneficial ownership of securities

SAN FRANCISCO,Nov. 07, 2024(GLOBE NEWSWIRE) --Third Harmonic Bio, Inc.(Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases, today announced that management will participate in the following upcoming conferences:

  • Natalie Holles, Chief Executive Officer, will participate in a fireside chat at the Stifel 2024 Healthcare Conference onTuesday, November 19, 2024, at 3:00 p.m. EST
  • Chris Murphy, Chief Financial and Business Officer, will participate in a fireside chat at theJefferies London Healthcare ConferenceonTuesday, November 19, 2024, at11:00 a.m. GMT/6:00 a.m. EST

A live audio webcast of each fireside chat will be available within theInvestors & Mediasection of the Third Harmonic Bio website. Archived replays will be accessible for 90 days following the event.

AboutThird Harmonic Bio, Inc.Third Harmonic Biois a clinical stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases through the development of novel, highly selective, small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Early clinical studies demonstrate that KIT inhibition has the potential to revolutionize the treatment of a broad range of mast-cell-mediated inflammatory diseases, and that a titratable, oral small molecule inhibitor may provide the optimal therapeutic profile against this target. Third Harmonic Bio’s lead product candidate,THB335, is a titratable, oral, small molecule inhibitor that is currently in a Phase 1 clinical trial. For more information, please visit theThird Harmonic Biowebsite:www.thirdharmonicbio.com.

Investor and Media Contact:Lori Murraylori.murray@thirdharmonicbio.com

Third Harmonic Bio

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com